Latterly, we observed that administering the anti-VEGF/IL8 nAbs during the period of hypoxia development (i.e., concurrent with initiating enzalutamide therapy) effected a resolution of drug-sensitive LNCaP tumors to below detectable thresholds within 14 days, with sustained tumor control observed for a period extending greater than 30 days post-cessation of treatment, consistent with a durable response. This evidence concerns the gene CXCL8 and neoplasm.